循环肿瘤DNA在肝细胞癌中的临床应用研究进展

摘要/Abstract

摘要： 肝细胞癌(HCC)作为发病率和致死率均较高的消化道恶性肿瘤,导致了十分严重的社会负担。指南也推荐开发更为准确的无创生物学指标来改进对HCC的早期诊断及预后评估,从而改善患者总体预后。循环肿瘤DNA(ctDNA)的检测属于液体活检技术,其检测方法简便,可以反映肿瘤细胞基因突变及负荷的特点。在用于HCC的临床诊断及预后评估研究方面,ctDNA作为无创指标显示出了较高的应用价值。随着对ctDNA检测技术的不断改进,其在用于HCC临床诊治方面的价值也将得到进一步的拓展,从而使更多HCC患者获益。

关键词: 肝细胞癌, 循环肿瘤DNA, 肿瘤突变负荷, 诊断, 预后

朱鹏, 彭明珠, 吴莉莉, 郭世民. 循环肿瘤DNA在肝细胞癌中的临床应用研究进展[J]. 肝脏, 2025, 30(2): 268-271.

/ 推荐

参考文献

[1] Vogel A,Meyer T,Sapisochin G,et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360): 1345-1362.
[2] 范芯铷,刘铭佳,王庆,等. 原发性肝癌的发病机制及治疗进展[J]. 肝脏, 2023, 28(4): 391-392.
[3] 国家卫生健康委员会办公厅. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2022, 40(5): 893-918.
[4] Kinsey E,Lee H M. Management of hepatocellular carcinoma in 2024: the multidisciplinary paradigm in an evolving treatment landscape[J]. Cancers (Basel), 2024, 16(3):666.
[5] Panneerselvam S,Wilson C,Kumar P,et al. Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options[J]. Cell Adh Migr, 2023, 17(1): 1-21.
[6] Manea I,Iacob R,Iacob S,et al. Liquid biopsy for early detection of hepatocellular carcinoma[J]. Front Med (Lausanne), 2023, 10: 1218705.
[7] Zhou Z,Xu X,Liu Y,et al. Liquid biopsy in hepatocellular carcinoma[J]. Methods Mol Biol, 2023, 2695: 213-225.
[8] Jeepalyam S,Sheel A,Ejaz A,et al. Is cell-free DNA testing in hepatocellular carcinoma ready for prime time?[J]. Int J Mol Sci, 2023, 24(18):14231.
[9] Aquino I M C,Pascut D. Liquid biopsy: new opportunities for precision medicine in hepatocellular carcinoma care[J]. Ann Hepatol, 2024, 29(2): 101176.
[10] Bardol T,Pageaux G P,Assenat E,et al. Circulating tumor DNA clinical applications in hepatocellular carcinoma: current trends and future perspectives[J]. Clin Chem, 2024, 70(1): 33-48.
[11] Zhu Q,Xie J,Mei W,et al. Methylated circulating tumor DNA in hepatocellular carcinoma: a comprehensive analysis of biomarker potential and clinical implications[J]. Cancer Treat Rev, 2024, 128: 102763.
[12] Nafar S,Hosseini K,Shokrgozar N,et al. An investigation into cell-free DNA in different common cancers[J]. Mol Biotechnol, 2024, 66(12):3462-3474.
[13] Ho H-Y,Chung K-K,Kan C-M,et al. Liquid biopsy in the clinical management of cancers[J]. Int J Mol Sci, 2024, 25(16):8594.
[14] Nam H,Lee E,Yang H,et al. PROMER technology: a new real-time PCR tool enabling multiplex detection of point mutation with high specificity and sensitivity[J]. Biol Methods Protoc, 2024, 9(1): bpae041.
[15] da Silva T F,de Azevedo JC Jr,Teixeira E B,et al. From haystack to high precision: advanced sequencing methods to unraveling circulating tumor DNA mutations[J]. Front Mol Biosci, 2024, 11: 1423470.
[16] Chan Y T,Zhang C,Wu J,et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma[J]. Mol Cancer, 2024, 23(1): 189.
[17] Aalami A H,Aalami F,Aliabadi E K,et al. Detection of circulating cell-free DNA to diagnose hepatocellular carcinoma in chinese population: a systematic review and meta-analysis[J]. Curr Med Chem, 2024, 31(22): 3345-3359.
[18] Yinzhong W,Miaomiao W,Xiaoxue T,et al. Diagnostic accuracy of circulating-free DNA for the determination of hepatocellular carcinoma: a systematic review and meta-analysis[J]. Expert Rev Mol Diagn, 2023, 23(1): 63-69.
[19] Chang Y,Jeong S W,Jang J Y,et al. The diagnostic value of circulating tumor DNA in hepatitis B virus induced hepatocellular carcinoma: a systematic review and meta-analysis[J]. J Liver Cancer, 2022, 22(2): 167-177.
[20] Li J J,Lv Y,Ji H. Diagnostic performance of circulating tumor DNA as a minimally invasive biomarker for hepatocellular carcinoma: a systematic review and meta-analysis[J]. PeerJ, 2022, 10: e14303.
[21] Lin D,Luo R,Ye Z,et al. Genomic characterization of early-stage hepatocellular carcinoma patients with hepatitis B using circulating tumor DNA[J]. Clin Res Hepatol Gastroenterol, 2023, 47(7): 102161.
[22] Lin S Y,Xia W,Kim A K,et al. Novel urine cell-free DNA methylation markers for hepatocellular carcinoma[J]. Sci Rep, 2023, 13(1): 21585.
[23] Chen L,Wu T,Fan R,et al. Cell-free DNA testing for early hepatocellular carcinoma surveillance[J]. EBioMedicine, 2024, 100: 104962.
[24] Wehrle C J,Hong H,Kamath S,et al. Tumor mutational burden from circulating tumor DNA predicts recurrence of hepatocellular carcinoma after resection: an emerging biomarker for surveillance[J]. Ann Surg, 2024, 280(3): 504-513.
[25] Fu Y,Yang Z,Hu Z,et al. Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies[J]. Hepatol Int, 2022, 16(4): 868-878.
[26] Xu Y,Cai J,Zhong K,et al. Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection[J]. Front Oncol, 2023, 13: 1119744.
[27] Lian S,Lu C,Li F,et al. Monitoring hepatocellular carcinoma using tumor content in circulating cell-free DNA[J]. Clin Cancer Res, 2024, 30(13): 2772-2779.
[28] Sogbe M,Bilbao I,Marchese F P,et al. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment[J]. Clin Mol Hepatol, 2024, 30(2): 177-190.
[29] Watanabe T,Suzuki Y,Kuroda H,et al. Circulating cell-free DNA as a biomarker for prognosis and response to systemic therapy in patients with unresectable hepatocellular carcinoma[J]. Oncology, 2023, 101(11): 714-722.
[30] Mohamed Y I,Lee S S,Demir T,et al. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab[J]. Cancer Biomark, 2024, 41(1): 83-91.